Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through Aclaris Therapeutics’ multi-trial disclosures, royalty agreements, and cash runway notes can exceed 250 pages per filing. Pinpointing when a kinase inhibitor enters Phase 2 or tracking executive option exercises shouldn’t require a doctorate in regulatory science.
Stock Titan’s AI-powered analysis decodes every Aclaris Therapeutics SEC filing in real time. Need the Aclaris Therapeutics quarterly earnings report 10-Q filing? Our platform highlights R&D spend, liquidity updates, and segment revenue in plain English. Wondering about Aclaris Therapeutics insider trading Form 4 transactions? Receive instant alerts the moment executives buy or sell shares. From the Aclaris Therapeutics annual report 10-K simplified to each Aclaris Therapeutics 8-K material events explained, our summaries surface trial milestones, licensing income, and risk factors in minutes rather than hours.
Investors use these insights to:
- Monitor Aclaris Therapeutics Form 4 insider transactions real-time before pivotal data releases
- Compare quarter-over-quarter R&D burn without wading through accounting footnotes
- Review Aclaris Therapeutics proxy statement executive compensation alongside dilution projections
- Assess cash needs via shelf registration S-3 filings
Aclaris Therapeutics (ACRS) reported Q3 2025 results. Total revenue was $3.299 million (contract research $0.485M; licensing $2.814M). Operating expenses rose on pipeline investment, with R&D at $13.028 million and G&A at $4.871 million. The company recorded non‑cash royalty income of $0.716 million from the OLUMIANT royalty sale structure.
Net loss was $14.614 million versus $7.586 million a year ago, reflecting higher development spend. Year‑to‑date, net loss was $45.128 million. The balance sheet showed cash, cash equivalents and marketable securities of $167.2 million as of September 30, 2025, and stockholders’ equity of $120.1 million. Management states its resources are sufficient for more than 12 months from issuance. Shares outstanding were 108,345,239 as of October 31, 2025.
Segment data highlight therapeutics as the primary driver: Q3 R&D included bosakitug $3.062M, ATI‑2138 $1.469M, and ATI‑052 $1.837M, alongside discovery $2.340M. Deferred income related to the royalty sale was $3.925M current and $17.492M non‑current.
Aclaris Therapeutics will host an in-person and virtual R&D Day on October 14, 2025 at 8:00 a.m. ET, with a live webcast available on the Investors Events page. The accompanying company presentation is furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). The information in Item 7.01 and Exhibit 99.1 is not deemed “filed” under the Exchange Act or Securities Act, except if expressly incorporated by reference.
FAQ
What is the current stock price of Aclaris Therapeutics (ACRS)?
What is the market cap of Aclaris Therapeutics (ACRS)?
